Jump to navigation

  • IHME
  • GHDx
  • GBD Compare
Home
Main menu
  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
      • IHME Foundations
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Online Training
    • Workshops
  • About
    • Our Principles
    • Racism is a public health issue.
    • Senior Management Team
    • Faculty
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Explore section

COVID-19 resources

  • Home
  • COVID-19 projections
  • Policy briefings
  • FAQs
  • Estimate downloads
  • Multimedia
  • Press releases
  • Media coverage
  • Publications
  • Acknowledgements
  • Contact us

COVID-19 vaccine efficacy summary


Twitter
Facebook
Google+
LinkedIn
Pinterest
Email
Print
Publication date: 
March 4, 2021

To project future COVID-19 trends, IHME centralizes and updates all available data on vaccine efficacy. This document summarizes the available data and key underlying assumptions of IHME’s projections. This page is updated monthly; for interim updates please see the "Methods updates" section of our weekly policy briefings.

Review and summary of available data

Using all publications, reports, and news articles, we review all available data to find how effective vaccines are at achieving multiple outcomes. “Vaccine efficacy” is not a single number – we capture:

  1. Prevention of symptomatic disease: a vaccine’s efficacy at causing an exposed individual not to suffer the symptoms of COVID-19 infection. The person can contract the virus but will not develop disease.
  2. Prevention of severe disease: a vaccine’s efficacy at preventing an exposed person from developing more serious symptoms that often require hospitalization.
  3. Prevention of infection: a vaccine’s efficacy at stopping transmission of the virus from one person to another. An exposed person will not contract the virus, and by definition they will also not develop symptoms or disease.

For each of the outcomes above, we also capture the differences by:

  1. First dose versus complete regimen (not applicable for 1-dose vaccines, like Johnson & Johnson)
  2. Asymptomatic, any symptomatic, or severe disease
  3. Variant of COVID-19: D614G (ancestral type*), B.1.1.7, B.1.351, P.1

*Ancestral type is the predominant global strain of a virus.

Where genomic sequencing of cases did not occur, we use the location of the study as a proxy for the predominant variant type. For example, studies in South Africa were assumed to represent efficacy against B.1.351.

Data available today consist of clinical trials and several quasi-observational studies. Table 1 summarizes the available data to date:

Table 1: Available vaccine efficacy data

Estimating vaccine efficacy for COVID-19 projections

Currently, the IHME model uses the following inputs of vaccine efficacy, separated by variant:

  1. Efficacy at preventing symptomatic disease
  2. Efficacy at preventing infection

Importantly, vaccine outcomes do not seem to differ for D614G and B.1.1.7. We assume the efficacy against B.1.351 is the same for P.1, as there are currently very limited data for the P.1 variant, and these two variants have a similar mutation.

Wherever data are available (see Table 1) we use available data, and where we do not yet have data, we take different approaches based on variant, vaccine, and outcome. We make estimates to complete the empty cells in Table 2:

Table 2: Vaccine efficacy by coronavirus variant, available data

Vaccine                                                                

Efficacy at preventing disease:

D614G & B.1.1.7

Efficacy at preventing infection:

D614G & B.1.1.7

Efficacy at preventing disease:

B.1.351 & P.1

Efficacy at preventing infection:

B.1.351 & P.1

Pfizer

95%

86%

 

 

Moderna

94%

 

 

 

AstraZeneca

74%

52%

10%

 

Johnson & Johnson

72%

72%

64%

 

Sputnik V

92%

 

 

 

Novavax

89%

 

49%

 

CoronaVac

50%

 

 

 

Sinopharm

73%

 

 

 

CanSinoBIO

66%

 

 

 

Other mRNA vaccines

 

 

 

 

All other vaccines

 

 

 

 

 

To estimate efficacy at preventing disease for D614G and B.1.1.7

mRNA vaccines: We assume the same efficacy as Pfizer-BioNTech and Moderna (95%).

CoronaVac: We use the Brazil arm of the CoronaVac trial, as it has the largest number of cases.

All other vaccines: We assume 75% efficacy.

To estimate efficacy at preventing infection for D614G and B.1.1.7

Moderna: We use the ratio between preventing disease and preventing infection (0.91) from the UK SIREN study of Pfizer-BioNTech.

Johnson & Johnson: Based on trial results, we assume the effect is the same for preventing disease and infection.

All other vaccines: We use the average infection-to-disease ratio from all available studies (0.87).

To estimate efficacy and preventing disease for variants B.1.351 and P.1

All vaccines without available data: We find the ratio of preventing disease between D614G and the B.1.351 and P.1 variants from the Novavax and Johnson & Johnson trials,* and apply this ratio to all other vaccines to estimate efficacy at preventing disease (0.76).

*We intentionally exclude the AstraZeneca trial results in this average as it is so much lower than other vaccines.

To estimate efficacy at preventing infection for variants B.1.351 and P.1

All vaccines: Use same infection-to-disease ratio as estimated in D614G (0.87).

Table 3 shows the final model inputs for vaccine efficacy at preventing disease and infection, by vaccine and variant type.

Table 3: Vaccine efficacy by coronavirus variant, available data and modeled estimates

Vaccine

Efficacy at preventing disease:

D614G & B.1.1.7

Efficacy at preventing infection:

D614G & B.1.1.7

Efficacy at preventing disease:

B.1.351 & P.1

Efficacy at preventing infection:

B.1.351 & P.1

Pfizer

95%

86%

72%

63%

Moderna

94%

85%

72%

62%

AstraZeneca

74%

52%

10%

9%

Johnson & Johnson

72%

72%

64%

56%

Sputnik V

92%

80%

70%

61%

Novavax

89%

77%

49%

43%

CoronaVac

50%

43%

38%

33%

Sinopharm

73%

63%

56%

48%

CanSinoBIO

66%

57%

50%

44%

Other mRNA vaccines

95%

83%

72%

63%

All other vaccines

75%

65%

57%

50%

 

 

Related Content

Projects

COVID-19 resources
IHME’s COVID-19 projections were developed in response to requests from the University of Washington School of Medicine and other US hospital systems and state...

COVID-19 resources

  • Home
  • COVID-19 projections
  • Policy briefings
  • FAQs
  • Estimate downloads
  • Multimedia
  • Press releases
  • Media coverage
  • Publications
  • Acknowledgements
  • Contact us

Sign up for IHME News

Stay connected

     

IHME

Institute for Health Metrics and Evaluation

Population Health Building/Hans Rosling Center

3980 15th Ave. NE, Seattle, WA 98195

UW Campus Box #351615

Tel: +1-206-897-2800

Fax: +1-206-897-2899

© 2020 University of Washington

  • Privacy policy
  • Login

  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Online Training
    • Workshops
  • About
    • Our Principles
    • Racism is a public health issue.
    • Senior Management Team
    • Faculty
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Projects

  • Global Burden of Disease (GBD)
  • Disease Control Priorities Network (DCPN)
  • ABCE+: A Focus on Antiretroviral Therapy (ART)
  • Access, Bottlenecks, Costs, and Equity (ABCE)
  • Efficacy to Effectiveness
  • Viral Load Pilot
  • Salud Mesoamérica Initiative
  • Improving Methods to Measure Comparable Mortality by Cause
  • Verbal Autopsy (VA)
  • Disease Expenditure (DEX)
  • State-level disease burden initiative in India
  • US Counties Drivers of Health Study
  • University of Washington Center for Health Trends and Forecasts